"Palivizumab Therapy for RSV-bronchiolitis"

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
There is a growing body of literature suggesting that monoclonal antibody could be efficacious in infants with RSV-bronchiolitis, well tolerated with no or clinically insignificant adverse effects. \"The investigators hypothesize that a single dose of iv palivizumab 15 mg/kg in diagnosed infants \<3 months old with RSV bronchiolitis will result in fewer infants with readmissions to infirmary/observation or hospital for relapse during 3 weeks of follow-up after discharge\".
Epistemonikos ID: 11f3b5fa5cfa9e9a1d1bf01d06c23e4217bde944
First added on: Mar 23, 2020